Teva, Viatris revive patent challenge on J&J's long-acting schizophrenia blockbuster Invega Sustenna
After incurring a loss in New Jersey federal court in 2021, Teva and Viatris have successfully resurrected challenges to the last remaining U.S. patent on a lucrative Johnson & Johnson schizophrenia ...
Paliperidone (as palmitate) 273mg, 410mg, 546mg, 819mg; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp) for at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results